Share on StockTwits

AcelRx Pharmaceuticals (NASDAQ:ACRX) has received a consensus rating of “Buy” from the nine analysts that are currently covering the stock, StockRatingsNetwork reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $13.06.

AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 7.46 on Thursday. AcelRx Pharmaceuticals has a 1-year low of $6.04 and a 1-year high of $13.64. The stock’s 50-day moving average is $7.46 and its 200-day moving average is $9.8. The company’s market cap is $323.6 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. On average, analysts predict that AcelRx Pharmaceuticals will post $-1.09 earnings per share for the current fiscal year.

A number of research firms have recently commented on ACRX. Analysts at Jefferies Group cut their price target on shares of AcelRx Pharmaceuticals from $17.00 to $16.00 in a research note on Tuesday, August 12th. They now have a “buy” rating on the stock. Separately, analysts at Cowen and Company reiterated an “outperform” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, July 29th. They now have a $14.00 price target on the stock, down previously from $15.00. Finally, analysts at Piper Jaffray downgraded shares of AcelRx Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $8.00 price target on the stock, down previously from $14.00.

AcelRx Pharmaceuticals, Inc is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.